Document is current
Any future updates will be listed below
-
Authors
Mielnik, Pawel https://orcid.org/0000-0002-3894-5371
Sexton, Joseph
Lie, Elisabeth
Bakland, Gunnstein
Loli, Liz P.
Kristianslund, Eirik K.
Rødevand, Erik
Lexberg, Åse S.
Kvien, Tore K.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01581294 at ClinicalTrials.govDocuments that mention this clinical trial
Does Older Age have an Impact on Rituximab Efficacy and Safety? Results from the NOR-DMARD Register
https://doi.org/10.1007/s40266-020-00782-x
- License Information
-
More Information
Article History
First Online: 9 July 2020
Compliance with Ethical Standards
:
: No funding was received for the conduct of this study or preparation of this article.
: Tore K. Kvien has received fees for speaking and/or consulting from AbbVie, Biogen, Celltrion, Egis, Eli Lilly, Hikma, MSD, Mylan, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz, Sanofi, and UCB and has received research funding to Diakonhjemmet Hospital from AbbVie, BMS, MSD, Pfizer, Roche and UCB. Gunnstein Bakland has received speakers fees from Novartis and Abbvie and is on the advisory board for Pfizer, Novartis and Celgene. Pawel Mielnik, Joseph Sexton, Elisabeth Lie, Liz P. Loli, Eirik K. Kristianslund, Erik Rødevand and Åse S. Lexberg have no conflicts of interest that are directly relevant to the content of this article.
: NOR-DMARD has been approved by the local ethics committee (REK sør-øst, 2011/1339), the Data Inspectorate and the Norwegian Medicines Agency.
: All patients signed the informed consent form.
